Patrick, McKenzie
Gu, Zhimin
Zhang, Gen
Wynn, R. Max http://orcid.org/0000-0002-1879-2136
Kaphle, Pranita
Cao, Hui
Vu, Hieu
Cai, Feng
Gao, Xiaofei
Zhang, Yuannyu
Chen, Mingyi http://orcid.org/0000-0001-6754-0480
Ni, Min
Chuang, David T.
DeBerardinis, Ralph J. http://orcid.org/0000-0002-2705-7432
Xu, Jian http://orcid.org/0000-0003-1988-7337
Funding for this research was provided by:
U.S. Department of Defense (PR191670)
U.S. Department of Health & Human Services | National Institutes of Health (R35CA22044901, R01CA230631, R01CA259581, R01DK111430, R21AI158240)
Cancer Prevention and Research Institute of Texas (RP180778, RP180504, RP190417, RP220337, RP220375)
Article History
Received: 28 February 2022
Accepted: 14 October 2022
First Online: 28 November 2022
Competing interests
: M.P. and J.X. have a pending patent application for the use of BCAT isozymes to treat metabolic disorders. M.P., J.X., and The University of Texas Southwestern Medical Center have a financial interest in the pending patent application.